Posts

Showing posts from June, 2025

Summit Therapeutics falls after mixed data from late-stage study of Ivonescimab plus chemotherapy cancer trial in EGFR-mutated Lung Cancer (NSCLC): Update

Image
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced (May 30, 2025) topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab, successfully met the progression-free survival (PFS) primary endpoint and showed a positive trend in the other primary endpoint, overall survival (OS). HARMONi is a multiregional, double-blinded, placebo-controlled, Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI). This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials in showing either a P...

Evidence-Based Strategies for Cancer Prevention: I-Prevent Cancer Protocol (2025 Edition)

Image
Abstract Cancer remains a leading cause of mortality worldwide, with incidence rates projected to rise significantly in the coming decades. While advances in treatment have modestly improved survival, prevention through modifiable risk factors remains underemphasized. This review synthesizes current evidence on the role of diet, lifestyle, and dietary supplements in cancer prevention, drawing on systematic reviews, meta-analyses, and major guideline recommendations. The I-PREVENT CANCER protocol is introduced as a practical, evidence-based framework for reducing cancer risk. Introduction Despite substantial investment in cancer research, global cancer mortality remains high, with approximately 10 million deaths annually. The incidence of common cancers such as breast, lung, and colon cancer is expected to increase by over 75% between 2022 and 2050. While treatment advances offer incremental improvements in survival, prevention strategies—particularly those related to diet and lifestyle...